GLP-1 Drugs, Vitamin D and Resistance Training Reshape Diabetes and Obesity Care

Metabolic health research is moving fast, and this MedPage Today roundup captures several findings that matter for anyone focused on longevity and disease prevention. The breadth of topics — from post-surgical drug timing to vitamin D economics — reflects how multi-layered the fight against diabetes and obesity has become.

One of the most actionable findings comes from a microsimulation model using national U.S. data, published in Lancet Regional Health Americas. Vitamin D supplementation in adults with prediabetes was projected to reduce lifetime cumulative diabetes incidence by 8% and deliver a net monetary benefit of over $15,000 per person. For the millions of Americans in the prediabetes zone, this is a low-cost, low-risk intervention worth discussing with a physician.

On the exercise front, a JAMA Network Open study of more than 140,000 healthcare professionals found that long-term resistance training was associated with a substantially lower risk of developing type 2 diabetes. This reinforces growing evidence that muscle-building activity — not just cardio — is a cornerstone of metabolic protection and healthy aging.

GLP-1 therapies continue to expand in scope. U.S. cohort data published in eClinicalMedicine showed that incretin-based therapies after bariatric surgery produced clinically meaningful additional weight loss, with effects dependent on dose and timing. Meanwhile, investigational oral GLP-1 agent CX11 achieved 11.5% weight loss by week 36 in a phase II trial, and bofanglutide reduced HbA1c in a phase IIb trial of Chinese adults with type 2 diabetes, though gastrointestinal side effects were common.

Regulatory and hormonal health news also featured prominently. HHS proposed removing age-related and prostate-related restrictions from testosterone labeling, a move with significant implications for older men. A systematic review also found that women with a history of idiopathic premature adrenarche carry elevated long-term risk of insulin resistance and hyperandrogenism — a clinically underrecognized connection.